Gilead reconfirms India Sovaldi plans despite patent challenge
This article was originally published in Scrip
Executive Summary
Gilead Sciences has underscored that the Sovaldi (sofosbuvir) patent battle in India is far from over and that its licensing deals with seven partners stand unaffected. The company has just had one of the patent applications for its hepatitis C therapy rejected.